View Financial HealthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsXylo Technologies 배당 및 자사주 매입배당 기준 점검 0/6Xylo Technologies 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-8.3%자사주 매입 수익률총 주주 수익률-8.3%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Aug 23L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO).L.I.A. Pure Capital Ltd. proposed to acquire remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO) for $3.5 million on March 4, 2025. The Amended Request increases Pure Capital’s proposal for the acquisition of the remaining 91.13% of the Company’s issued and outstanding share capital to an updated purchase price of $0.13125 per ordinary share of the Company (or $5.25 per American Depositary Share. The Amended Request further clarifies, subject to shareholder approval of the Arrangement, that (i) Pure Capital commits to purchase restricted share units granted to the Company’s employees, officers and directors that are subject to acceleration upon a change of control; and (ii) the Company will purchase customary run-off insurance as of the date the Arrangement becomes effective. The Court has given the Company until March 12, 2025, to submit a response to the Amended Request. The parties will finalize the Arrangement only if the parties satisfy or waive certain conditions including Israeli court approval. The board of directors of Xylo Technologies Ltd has decided not to object and has approved the proposal, considering it to be fair. As of May 27, 2025, Xylo Technologies Ltd shareholders approved the transaction in the general meeting. The transaction remains subject to approval by the Tel Aviv District Court. As of June 05, 2025, Viewbix Inc. has received approval for its shares of common stock to be listed on the Nasdaq Capital Market. As of June 22, 2025, the district court of Tel Aviv approved the arrangement between Xylo and its shareholders. L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO) on August 22, 2025.New Risk • May 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 80% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Market cap is less than US$10m (US$6.66m market cap). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).Reported Earnings • May 02Full year 2024 earnings released: US$8.10 loss per share (vs US$25.34 loss in FY 2023)Full year 2024 results: US$8.10 loss per share (improved from US$25.34 loss in FY 2023). Revenue: US$29.9m (down 67% from FY 2023). Net loss: US$6.03m (loss narrowed 62% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (US$3.66m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Nancy Agmon-Levin was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Sep 26First half 2024 earnings released: US$11.33 loss per share (vs US$13.39 loss in 1H 2023)First half 2024 results: US$11.33 loss per share (improved from US$13.39 loss in 1H 2023). Revenue: US$19.3m (down 64% from 1H 2023). Net loss: US$8.17m (flat on 1H 2023). Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 27 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 23Full year 2023 earnings released: US$9.50 loss per share (vs US$6.04 loss in FY 2022)Full year 2023 results: US$9.50 loss per share (further deteriorated from US$6.04 loss in FY 2022). Revenue: US$91.7m (flat on FY 2022). Net loss: US$16.0m (loss widened 63% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 9 percentage points per year, which is a significant difference in performance.공고 • Apr 19Medigus Ltd.(NasdaqCM:MDGS) dropped from NASDAQ Composite IndexMediGus Ltd. has been removed from Nasdaq Composite Index.New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$4.74m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).공고 • Dec 26Medigus Ltd. Announces Launch of Unique Pilot of A Wireless Charging SolutionMedigus Ltd. announced the launch of a unique pilot of a wireless charging solution to meet the growing demand for electric vehicle (EV) charging in automated parking systems. This project was led by Charging Robotics Ltd., an innovator in wireless charging solutions and a subsidiary of Fuel Doctor Holdings Inc., a Delaware corporation listed on the OTC Market and owned by Medigus (67.15%). Charging Robotics specializes in developing cutting-edge wireless charging solutions designed to seamlessly integrate into the evolving landscape of electric vehicle (EV) infrastructure. Charging Robotics is at the forefront of innovation, focusing on the creation of wireless charging systems that can be deployed in various settings, including automated parking systems. In August 2023, the company announced that it started a pilot project with an automatic car park provider in Israel to evaluate Charging Robotics' wireless charging system for electric vehicles. For that purpose, in November 2023, the company secured funding from the Israel Innovation Authority to fund the pilot project. Between 2023 and 2032, this market is estimated to register a CAGR of 11.4%. Alongside the expected growth in the EV market, the combination of EVs and automated parking creates potential for a more sustainable and efficient future for transportation. The wireless charging system is set to answer the unmet need of charging EVs in automatic car parks. Automatic car parks are gaining popularity as they offer an ultra-efficient solution to park cars, while also reducing expensive real estate costs. However, since these are automated facilities, currently there is no way for the driver to connect a charging cable to the vehicle. This is a major concern and a market inhibit for automated parking manufacturers and EV manufacturers, particularly in areas where electric vehicles are growing rapidly- this is the con Charging Robotics aiming to address. Besides enabling EV charging in automatic car parks, the wireless charging system has numerous advantages, including: Seamless Integration: the wireless charging system will be seamlessly integrated into the automatic car park infrastructure, requiring minimal modifications to the existing layout. This ensures a minimum installation process while maximizing parking capacity. Convenient Charging Experience: drivers will start the system using a dedicated smart phone application, which will also notify the driver about the charging process. Scalability and Adaptability: the system's modular design enables easy scalability, allowing the parking lot operator to increase the number of chargers in the facility based on the number of electric vehicles. The system will be able to charge all electric vehicles at efficiencies of >93% which is outstanding for wireless charging systems.New Risk • Oct 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$7.58m market cap). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (5.8% increase in shares outstanding).New Risk • Jul 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$8.01m market cap). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding).공고 • Jul 01Medigus Ltd., Annual General Meeting, Aug 07, 2023Medigus Ltd., Annual General Meeting, Aug 07, 2023, at 10:00 US Eastern Standard Time. Location: Law Offices, 16 Abba Hillel Silver Rd. Ramat - Gan Israel Agenda: To consider approval of the re-election of Mr. Eli Cohen to serve as a director of the Company; to consider approval of a grant of restricted share units to the Company’s Chief Executive Officer, Chief Financial Officer and the Company’s directors; and Approval and ratification of the re-appointment of Brightman Almagor Zohar & Co., a member firm of Deloitte Touche Tohmatsu Limited, company's independent auditors for the year ending December 31, 2023, and its service until the next annual general meeting of shareholders to be held in 2024.공고 • Jun 08existing shareholders and office holders in ScoutCam acquired 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million.existing shareholders and office holders in ScoutCam acquired 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million on June 6, 2023. existing shareholders and office holders in ScoutCam completed the acquisition of 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million on June 6, 2023.Reported Earnings • May 06Full year 2022 earnings released: US$6.04 loss per share (vs US$4.42 profit in FY 2021)Full year 2022 results: US$6.04 loss per share (down from US$4.42 profit in FY 2021). Revenue: US$91.9m (up US$81.7m from FY 2021). Net loss: US$9.82m (down 244% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.Price Target Changed • Nov 16Price target decreased to US$67.50Down from US$90.00, the current price target is provided by 1 analyst. New target price is 781% above last closing price of US$7.66. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$6.45 compared to earnings per share of US$4.42 last year.Seeking Alpha • Oct 19Medigus says ScoutCam appoints Yehu Ofer as CEOMedigus (NASDAQ:MDGS) has announced that ScoutCam (OTCQB:SCTC) appoints, Yehu Ofer as CEO, effective immediately. Mr. Ofer, 57, served as a colonel in the IAF, commanding two operational squadrons before commanding “Wing 15”, the optic and electronic intelligence wing of the IAF. He will lend his decades of experience to ScoutCam’s continued growth and success.Major Estimate Revision • Sep 30Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$12.4m to US$75.5m. EPS estimate fell from -US$0.02 to -US$0.43 per share. Medical Equipment industry in the US expected to see average net income growth of 9.6% next year. Consensus price target of US$4.50 unchanged from last update. Share price was steady at US$0.55 over the past week.Reported Earnings • Sep 24First half 2022 earnings released: US$0.15 loss per share (vs US$0.44 profit in 1H 2021)First half 2022 results: US$0.15 loss per share (down from US$0.44 profit in 1H 2021). Revenue: US$35.0m (up US$32.6m from 1H 2021). Net loss: US$3.59m (down 137% from profit in 1H 2021). Revenue is expected to decline by 49% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in the US are expected to grow by 7.8%. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.Seeking Alpha • Sep 23Medigus reports 1H resultsMedigus press release (NASDAQ:MDGS): 1H Net loss of $4.75M Revenue of $34.95M (+1362.3% Y/Y). Cash and cash equivalents as of June 30, 2022 were $22.1 million Shareholders’ equity improved to $53.19 million as of June 30, 2022, up from $51.43 million at December 31, 2021 Shares +16% PM.분석 기사 • Sep 22What Does Medigus Ltd.'s (NASDAQ:MDGS) Share Price Indicate?Medigus Ltd. ( NASDAQ:MDGS ), might not be a large cap stock, but it received a lot of attention from a substantial...Seeking Alpha • Sep 08Medigus board files a motion to approve an up to $1.6M dividend distributionMedigus (NASDAQ:MDGS) said on Thursday it had filed a motion with the Tel Aviv District Court Economic Department for approval of a dividend distribution up to of $1.6M The Company’s motion, if approved as requested, would permit the Company to distribute a dividend to the holders of the Company’s American Depositary Shares in proportion to their respective holdings. Medigus is seeking a court approval for a dividend distribution in light of various legal restrictions that nullified its ability to buy back its shares under a previous court approval for a buyback, the company said.분석 기사 • May 10Is Now An Opportune Moment To Examine Medigus Ltd. (NASDAQ:MDGS)?Medigus Ltd. ( NASDAQ:MDGS ), might not be a large cap stock, but it received a lot of attention from a substantial...Reported Earnings • May 01Full year 2021 earnings released: EPS: US$0.20 (vs US$0.65 loss in FY 2020)Full year 2021 results: EPS: US$0.20 (up from US$0.65 loss in FY 2020). Revenue: US$10.1m (up US$9.59m from FY 2020). Net income: US$6.79m (up US$11.1m from FY 2020). Profit margin: 67% (up from net loss in FY 2020). Over the next year, revenue is expected to shrink by 38% compared to a 9.8% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 25% share price gain to US$1.10, the stock trades at a trailing P/E ratio of 3.3x. Average forward P/E is 34x in the Medical Equipment industry in the US. Total loss to shareholders of 62% over the past three years.Valuation Update With 7 Day Price Move • Nov 23Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to US$1.22, the stock trades at a trailing P/E ratio of 3.6x. Average forward P/E is 35x in the Medical Equipment industry in the US. Total loss to shareholders of 64% over the past three years.Board Change • Oct 31High number of new directorsIndependent Chairman of the Board Eli Yoresh was the last director to join the board, commencing their role in 2020.분석 기사 • Sep 28We Believe Medigus' (NASDAQ:MDGS) Earnings Are A Poor Guide For Its ProfitabilityWe didn't see Medigus Ltd.'s ( NASDAQ:MDGS ) stock surge when it reported robust earnings recently. We think that...Reported Earnings • Sep 26First half 2021 earnings released: EPS US$0.44 (vs US$0.56 loss in 1H 2020)First half 2021 results: Net income: US$9.79m (up US$12.3m from 1H 2020). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Feb 10New 90-day high: US$3.69The company is up 84% from its price of US$2.01 on 11 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 XYLO 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: XYLO 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Xylo Technologies 배당 수익률 vs 시장XYLO의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (XYLO)n/a시장 하위 25% (US)1.3%시장 상위 25% (US)4.1%업계 평균 (Medical Equipment)2.1%분석가 예측 (XYLO) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 XYLO 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 XYLO 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 XYLO 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: XYLO 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/08/23 09:59종가2025/08/21 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Xylo Technologies Ltd는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Rommel DionisioAegis Capital CorporationJeffrey CohenLadenburg Thalmann & CompanyChristopher LewisRoth Capital Partners
공고 • Aug 23L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO).L.I.A. Pure Capital Ltd. proposed to acquire remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO) for $3.5 million on March 4, 2025. The Amended Request increases Pure Capital’s proposal for the acquisition of the remaining 91.13% of the Company’s issued and outstanding share capital to an updated purchase price of $0.13125 per ordinary share of the Company (or $5.25 per American Depositary Share. The Amended Request further clarifies, subject to shareholder approval of the Arrangement, that (i) Pure Capital commits to purchase restricted share units granted to the Company’s employees, officers and directors that are subject to acceleration upon a change of control; and (ii) the Company will purchase customary run-off insurance as of the date the Arrangement becomes effective. The Court has given the Company until March 12, 2025, to submit a response to the Amended Request. The parties will finalize the Arrangement only if the parties satisfy or waive certain conditions including Israeli court approval. The board of directors of Xylo Technologies Ltd has decided not to object and has approved the proposal, considering it to be fair. As of May 27, 2025, Xylo Technologies Ltd shareholders approved the transaction in the general meeting. The transaction remains subject to approval by the Tel Aviv District Court. As of June 05, 2025, Viewbix Inc. has received approval for its shares of common stock to be listed on the Nasdaq Capital Market. As of June 22, 2025, the district court of Tel Aviv approved the arrangement between Xylo and its shareholders. L.I.A. Pure Capital Ltd. completed the acquisition of remaining 91.13% stake in Xylo Technologies Ltd (NasdaqCM:XYLO) on August 22, 2025.
New Risk • May 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 80% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Market cap is less than US$10m (US$6.66m market cap). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
Reported Earnings • May 02Full year 2024 earnings released: US$8.10 loss per share (vs US$25.34 loss in FY 2023)Full year 2024 results: US$8.10 loss per share (improved from US$25.34 loss in FY 2023). Revenue: US$29.9m (down 67% from FY 2023). Net loss: US$6.03m (loss narrowed 62% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (US$3.66m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Nancy Agmon-Levin was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Sep 26First half 2024 earnings released: US$11.33 loss per share (vs US$13.39 loss in 1H 2023)First half 2024 results: US$11.33 loss per share (improved from US$13.39 loss in 1H 2023). Revenue: US$19.3m (down 64% from 1H 2023). Net loss: US$8.17m (flat on 1H 2023). Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 27 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 23Full year 2023 earnings released: US$9.50 loss per share (vs US$6.04 loss in FY 2022)Full year 2023 results: US$9.50 loss per share (further deteriorated from US$6.04 loss in FY 2022). Revenue: US$91.7m (flat on FY 2022). Net loss: US$16.0m (loss widened 63% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 9 percentage points per year, which is a significant difference in performance.
공고 • Apr 19Medigus Ltd.(NasdaqCM:MDGS) dropped from NASDAQ Composite IndexMediGus Ltd. has been removed from Nasdaq Composite Index.
New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$4.74m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).
공고 • Dec 26Medigus Ltd. Announces Launch of Unique Pilot of A Wireless Charging SolutionMedigus Ltd. announced the launch of a unique pilot of a wireless charging solution to meet the growing demand for electric vehicle (EV) charging in automated parking systems. This project was led by Charging Robotics Ltd., an innovator in wireless charging solutions and a subsidiary of Fuel Doctor Holdings Inc., a Delaware corporation listed on the OTC Market and owned by Medigus (67.15%). Charging Robotics specializes in developing cutting-edge wireless charging solutions designed to seamlessly integrate into the evolving landscape of electric vehicle (EV) infrastructure. Charging Robotics is at the forefront of innovation, focusing on the creation of wireless charging systems that can be deployed in various settings, including automated parking systems. In August 2023, the company announced that it started a pilot project with an automatic car park provider in Israel to evaluate Charging Robotics' wireless charging system for electric vehicles. For that purpose, in November 2023, the company secured funding from the Israel Innovation Authority to fund the pilot project. Between 2023 and 2032, this market is estimated to register a CAGR of 11.4%. Alongside the expected growth in the EV market, the combination of EVs and automated parking creates potential for a more sustainable and efficient future for transportation. The wireless charging system is set to answer the unmet need of charging EVs in automatic car parks. Automatic car parks are gaining popularity as they offer an ultra-efficient solution to park cars, while also reducing expensive real estate costs. However, since these are automated facilities, currently there is no way for the driver to connect a charging cable to the vehicle. This is a major concern and a market inhibit for automated parking manufacturers and EV manufacturers, particularly in areas where electric vehicles are growing rapidly- this is the con Charging Robotics aiming to address. Besides enabling EV charging in automatic car parks, the wireless charging system has numerous advantages, including: Seamless Integration: the wireless charging system will be seamlessly integrated into the automatic car park infrastructure, requiring minimal modifications to the existing layout. This ensures a minimum installation process while maximizing parking capacity. Convenient Charging Experience: drivers will start the system using a dedicated smart phone application, which will also notify the driver about the charging process. Scalability and Adaptability: the system's modular design enables easy scalability, allowing the parking lot operator to increase the number of chargers in the facility based on the number of electric vehicles. The system will be able to charge all electric vehicles at efficiencies of >93% which is outstanding for wireless charging systems.
New Risk • Oct 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$7.58m market cap). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (5.8% increase in shares outstanding).
New Risk • Jul 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$8.01m market cap). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding).
공고 • Jul 01Medigus Ltd., Annual General Meeting, Aug 07, 2023Medigus Ltd., Annual General Meeting, Aug 07, 2023, at 10:00 US Eastern Standard Time. Location: Law Offices, 16 Abba Hillel Silver Rd. Ramat - Gan Israel Agenda: To consider approval of the re-election of Mr. Eli Cohen to serve as a director of the Company; to consider approval of a grant of restricted share units to the Company’s Chief Executive Officer, Chief Financial Officer and the Company’s directors; and Approval and ratification of the re-appointment of Brightman Almagor Zohar & Co., a member firm of Deloitte Touche Tohmatsu Limited, company's independent auditors for the year ending December 31, 2023, and its service until the next annual general meeting of shareholders to be held in 2024.
공고 • Jun 08existing shareholders and office holders in ScoutCam acquired 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million.existing shareholders and office holders in ScoutCam acquired 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million on June 6, 2023. existing shareholders and office holders in ScoutCam completed the acquisition of 46.11% stake in ScoutCam Inc. (OTCPK:SCTC) from Medigus Ltd. (NasdaqCM:MDGS) for $6 million on June 6, 2023.
Reported Earnings • May 06Full year 2022 earnings released: US$6.04 loss per share (vs US$4.42 profit in FY 2021)Full year 2022 results: US$6.04 loss per share (down from US$4.42 profit in FY 2021). Revenue: US$91.9m (up US$81.7m from FY 2021). Net loss: US$9.82m (down 244% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
Price Target Changed • Nov 16Price target decreased to US$67.50Down from US$90.00, the current price target is provided by 1 analyst. New target price is 781% above last closing price of US$7.66. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$6.45 compared to earnings per share of US$4.42 last year.
Seeking Alpha • Oct 19Medigus says ScoutCam appoints Yehu Ofer as CEOMedigus (NASDAQ:MDGS) has announced that ScoutCam (OTCQB:SCTC) appoints, Yehu Ofer as CEO, effective immediately. Mr. Ofer, 57, served as a colonel in the IAF, commanding two operational squadrons before commanding “Wing 15”, the optic and electronic intelligence wing of the IAF. He will lend his decades of experience to ScoutCam’s continued growth and success.
Major Estimate Revision • Sep 30Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$12.4m to US$75.5m. EPS estimate fell from -US$0.02 to -US$0.43 per share. Medical Equipment industry in the US expected to see average net income growth of 9.6% next year. Consensus price target of US$4.50 unchanged from last update. Share price was steady at US$0.55 over the past week.
Reported Earnings • Sep 24First half 2022 earnings released: US$0.15 loss per share (vs US$0.44 profit in 1H 2021)First half 2022 results: US$0.15 loss per share (down from US$0.44 profit in 1H 2021). Revenue: US$35.0m (up US$32.6m from 1H 2021). Net loss: US$3.59m (down 137% from profit in 1H 2021). Revenue is expected to decline by 49% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in the US are expected to grow by 7.8%. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
Seeking Alpha • Sep 23Medigus reports 1H resultsMedigus press release (NASDAQ:MDGS): 1H Net loss of $4.75M Revenue of $34.95M (+1362.3% Y/Y). Cash and cash equivalents as of June 30, 2022 were $22.1 million Shareholders’ equity improved to $53.19 million as of June 30, 2022, up from $51.43 million at December 31, 2021 Shares +16% PM.
분석 기사 • Sep 22What Does Medigus Ltd.'s (NASDAQ:MDGS) Share Price Indicate?Medigus Ltd. ( NASDAQ:MDGS ), might not be a large cap stock, but it received a lot of attention from a substantial...
Seeking Alpha • Sep 08Medigus board files a motion to approve an up to $1.6M dividend distributionMedigus (NASDAQ:MDGS) said on Thursday it had filed a motion with the Tel Aviv District Court Economic Department for approval of a dividend distribution up to of $1.6M The Company’s motion, if approved as requested, would permit the Company to distribute a dividend to the holders of the Company’s American Depositary Shares in proportion to their respective holdings. Medigus is seeking a court approval for a dividend distribution in light of various legal restrictions that nullified its ability to buy back its shares under a previous court approval for a buyback, the company said.
분석 기사 • May 10Is Now An Opportune Moment To Examine Medigus Ltd. (NASDAQ:MDGS)?Medigus Ltd. ( NASDAQ:MDGS ), might not be a large cap stock, but it received a lot of attention from a substantial...
Reported Earnings • May 01Full year 2021 earnings released: EPS: US$0.20 (vs US$0.65 loss in FY 2020)Full year 2021 results: EPS: US$0.20 (up from US$0.65 loss in FY 2020). Revenue: US$10.1m (up US$9.59m from FY 2020). Net income: US$6.79m (up US$11.1m from FY 2020). Profit margin: 67% (up from net loss in FY 2020). Over the next year, revenue is expected to shrink by 38% compared to a 9.8% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 25% share price gain to US$1.10, the stock trades at a trailing P/E ratio of 3.3x. Average forward P/E is 34x in the Medical Equipment industry in the US. Total loss to shareholders of 62% over the past three years.
Valuation Update With 7 Day Price Move • Nov 23Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to US$1.22, the stock trades at a trailing P/E ratio of 3.6x. Average forward P/E is 35x in the Medical Equipment industry in the US. Total loss to shareholders of 64% over the past three years.
Board Change • Oct 31High number of new directorsIndependent Chairman of the Board Eli Yoresh was the last director to join the board, commencing their role in 2020.
분석 기사 • Sep 28We Believe Medigus' (NASDAQ:MDGS) Earnings Are A Poor Guide For Its ProfitabilityWe didn't see Medigus Ltd.'s ( NASDAQ:MDGS ) stock surge when it reported robust earnings recently. We think that...
Reported Earnings • Sep 26First half 2021 earnings released: EPS US$0.44 (vs US$0.56 loss in 1H 2020)First half 2021 results: Net income: US$9.79m (up US$12.3m from 1H 2020). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Feb 10New 90-day high: US$3.69The company is up 84% from its price of US$2.01 on 11 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.